



COMPANY OVERVIEW

Cardax is a life sciences company that devotes substantially all of its efforts to developing safe anti-inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. The safety and efficacy of Cardax's products have not been directly evaluated in clinical trials or confirmed by the FDA.

RECENT NEWS

Cardax's ZanthoSyn® is No. 1 Seller at GNC Hawaii Stores

Feb 17 2018, 8:00 AM EST

Cardax Inks Deal to Distribute ZanthoSyn® in China

Feb 17 2018, 8:00 AM EST

STOCK OVERVIEW

Symbol	CDXI
Exchange	OTCQB
Shares OS	122,299,516
Market Cap	\$35.47M
Last Price	\$0.29
52-Week Range	\$0.07 - \$0.59

INVESTOR RELATIONS

Cardax, Inc.
T: (808) 457-1400
investors@cardaxpharma.com

MANAGEMENT TEAM

David G. Watumull
President and CEO, Director

Gilbert M. Rishton, Ph.D.
Chief Science Officer

John B. Russell
Chief Financial Officer

David M. Watumull
Chief Operating Officer

Timothy J. King, Ph.D.
Vice President, Research

CARDAX, INC.

2800 Woodlawn Drive
Suite 129
Honolulu, HI 96822

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.